Gossamer Bio Inc. has filed for an initial public offering seeking to raise around $264.5 million.

Gossamer plans to list on Nasdaq under the symbol GOSS.

The San-Diego-based company’s focus in on discovering, developing and commercializing immunology-based therapeutics in the autoimmune, allergy/ inflammation, immune oncology and fibrosis disease areas

The underwriters of the offering include BofA Merrill Lynch, Leerink Partners, and Barclays.

In July of 2018, Gossamer raised $230 million in a Series B round. Earlier that year Gossamer had a $100 million Series A round.

Sheila Gujrathi is president and CEO.